Torrent Pharmaceuticals Ltd (IN:TORNTPHARM)
:TORNTPHARM
Top Page
Torrent Pharmaceuticals Ltd
(TORNTPHARM)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹4,354.00
▲(21.66% Upside)
Action:ReiteratedDate:10/17/25
Torrent Pharmaceuticals demonstrates strong financial performance with significant revenue and cash flow growth. However, technical indicators suggest a lack of strong momentum, and the stock appears overvalued with a high P/E ratio. These factors contribute to a moderate overall stock score.
Positive Factors
Free Cash Flow Strength
Sustained 42.48% free cash flow growth and FCF-to-net-income ~1.03 indicate durable cash generation. Reliable FCF funds R&D, capacity expansion, and M&A without heavy new debt, supports shareholder returns and cushions regulatory or pricing cycles in pharma.
Negative Factors
Net Profit Margin Pressure
Net margin (16.59%) lags gross and operating margins, implying expense, tax, or other drags. Persistent divergence limits retained earnings and true cash available after investment, constraining long-term reinvestment, dividend capacity, and ability to scale profitably.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Sustained 42.48% free cash flow growth and FCF-to-net-income ~1.03 indicate durable cash generation. Reliable FCF funds R&D, capacity expansion, and M&A without heavy new debt, supports shareholder returns and cushions regulatory or pricing cycles in pharma.
Read all positive factors
Torrent Pharmaceuticals Ltd (TORNTPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.36T
Dividend Yield0.84%
Average Volume (3M)7.49K
Price to Earnings (P/E)51.3
Beta (1Y)0.52
Revenue Growth9.11%
EPS Growth18.76%
CountryIN
Employees15,718
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)19.00
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio3.66
Price to Book (P/B)14.19
Price to Sales (P/S)9.52
P/FCF Ratio54.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)81.62
Revenue Forecast (FY)₹149.79B
Torrent Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic ...
How the Company Makes Money
Torrent Pharmaceuticals primarily makes money by selling prescription pharmaceutical formulations (finished dosage medicines) under its brands in India and in selected overseas markets. Its key revenue stream is domestic branded generics, where it...
Torrent Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 120.45B | 113.17B | 105.62B | 94.64B | 84.19B | 78.86B |
| Gross Profit | 89.59B | 84.33B | 77.75B | 66.36B | 58.81B | 56.51B |
| EBITDA | 39.06B | 37.19B | 35.00B | 28.81B | 21.41B | 25.34B |
| Net Income | 21.40B | 19.11B | 16.56B | 12.45B | 7.77B | 12.52B |
Balance Sheet | ||||||
| Total Assets | 155.15B | 149.90B | 150.61B | 150.12B | 131.00B | 140.75B |
| Cash, Cash Equivalents and Short-Term Investments | 10.33B | 6.91B | 10.04B | 7.23B | 5.83B | 7.38B |
| Total Debt | 28.22B | 32.02B | 40.22B | 53.68B | 40.70B | 48.74B |
| Total Liabilities | 70.66B | 73.99B | 82.04B | 88.14B | 71.47B | 82.37B |
| Stockholders Equity | 84.49B | 75.91B | 68.56B | 61.98B | 59.53B | 58.37B |
Cash Flow | ||||||
| Free Cash Flow | 8.42B | 19.74B | 28.33B | 17.94B | 16.00B | 16.76B |
| Operating Cash Flow | 10.38B | 25.85B | 32.66B | 23.68B | 18.03B | 20.11B |
| Investing Cash Flow | -2.14B | -5.40B | -1.68B | -24.15B | -1.97B | -4.49B |
| Financing Cash Flow | -8.26B | -22.98B | -27.80B | 770.00M | -17.81B | -16.56B |
Torrent Pharmaceuticals Ltd Technical Analysis
Negative
3578.85
Price Trends
4176.50
Negative
3991.05
Positive
3748.70
Positive
Market Momentum
-51.02
Positive
37.43
Neutral
30.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TORNTPHARM, the sentiment is Negative. The current price of 3578.85 is below the 20-day moving average (MA) of 4241.64, below the 50-day MA of 4176.50, and below the 200-day MA of 3748.70, indicating a neutral trend. The MACD of -51.02 indicates Positive momentum. The RSI at 37.43 is Neutral, neither overbought nor oversold. The STOCH value of 30.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TORNTPHARM.
Torrent Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹1.56T | 72.71 | ― | 0.46% | 16.43% | 35.35% | |
72 Outperform | ₹1.05T | 20.49 | ― | 0.57% | 15.49% | 64.37% | |
72 Outperform | ₹897.11B | 22.07 | ― | 1.19% | 14.01% | 14.62% | |
70 Outperform | ₹993.96B | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
68 Neutral | ₹982.10B | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
66 Neutral | ₹1.36T | 51.30 | ― | 0.84% | 9.11% | 18.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,027.60
928.22
29.95%
IN:CIPLA
Cipla Ltd
1,215.80
-185.52
-13.24%
IN:DIVISLAB
Divi's Laboratories Limited
5,881.25
521.95
9.74%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,191.45
103.20
9.48%
IN:LUPIN
Lupin Limited
2,293.55
384.11
20.12%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
891.55
56.52
6.77%
Torrent Pharmaceuticals Ltd Corporate Events
Torrent Pharma Publishes NCLT-Directed Shareholder Meeting Notice
Mar 28, 2026
Torrent Pharmaceuticals has notified stock exchanges that it has published newspaper advertisements in the Indian Express and Sandesh detailing a National Company Law Tribunal convened meeting of its equity shareholders. The meeting, ordered by th...
Torrent Pharma Sets Shareholder Meet to Approve J.B. Chemicals Amalgamation
Mar 27, 2026
Torrent Pharmaceuticals has called a court-convened general meeting of its equity shareholders on April 28, 2026, to be held via video conferencing as directed by the National Company Law Tribunal, Ahmedabad bench. Shareholders will be able to cas...
Torrent Pharma Enters GLP-1 Space With First Generic Oral Semaglutide in India
Mar 21, 2026
Torrent Pharmaceuticals has deepened its focus on chronic disease therapies, particularly in metabolic and lifestyle-driven conditions, by leveraging its broad international footprint and strong presence in cardiovascular, gastrointestinal and cen...
Torrent Pharma Plans Global Investor Meetings in March 2026
Feb 25, 2026
Torrent Pharmaceuticals Limited has announced a series of investor meetings with institutional investors across Singapore, Hong Kong and London in early March 2026, comprising both group sessions and one-on-one interactions. The roadshow-style eng...
Torrent Pharma to Shift Registered Office Within Ahmedabad
Jan 27, 2026
Torrent Pharmaceuticals Limited has approved the relocation of its registered office within Ahmedabad, shifting from its current premises at Torrent House, Off Ashram Road, to a new address at Avirat on Thaltej Shilaj Road, effective 29 January 20...
Torrent Pharma Raises ₹11,000 Crore via Multi-series Listed NCD Issue
Jan 19, 2026
Torrent Pharmaceuticals Ltd has raised long-term debt capital through a private placement of senior, secured, redeemable, listed, rated non-convertible debentures (NCDs) across four series, aggregating to an issue size of INR 110 billion. The NCDs...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.